Type 2 diabetes is caused by insulin resistance coupled with an inability to produce enough
insulin to control blood glucose, and thiazolidinediones (TZDs) are the only current …

Background Considering the global burden of diabetes and associated cardiovascular
disease, an urgent need exists for the best treatment, which should be based on the best …

Background The aim of the study was to evaluate the effect of delay in treatment
intensification (IT; clinical inertia) in conjunction with glycaemic burden on the risk of …

Aims To compare the sodium‐glucose‐cotransporter‐2 (SGLT‐2) inhibitor dapagliflozin with
dipeptidyl peptidase‐4 (DPP‐4) inhibitors with regard to risk associations with major …

Background Insulin shares a limited physiological concentration range with other endocrine
hormones. Not only too low, but also too high systemic insulin levels are detrimental for body …

Background Gabapentin and pregabalin are commonly prescribed medications to treat pain
in patients with diabetic neuropathy. Gabapentin and pregabalin can cause fluid retention …

Background Sulfonylureas are an effective and inexpensive treatment for type 2 diabetes.
There is conflicting data about the safety of these drugs regarding mortality and …

Importance Understanding cardiovascular outcomes of initiating second-line antidiabetic
medications (ADMs) may help inform treatment decisions after metformin alone is not …

Sulphonylureas have been commercially available since the 1950s, but their use continues
to be associated with controversy. Although adverse cardiovascular outcomes in some …

Since their introduction in clinical practice in the 1950's, Sulfonylureas (SUs) have remained
the main-stay of pharmacotherapy in the management of type 2 diabetes. Despite their well …